There are currently 293 active clinical trials seeking participants for Prostate Cancer research studies. The states with the highest number of trials for Prostate Cancer participants are California, New York, Texas and Ohio.
Evaluating Tolerability of EPUHRT with Brachytherapy Boost
NCT06817668
Recruiting
The purpose of this study is to evaluate the tolerability and toxicity of combining two radiation therapy methods for prostate cancer: Elective Pelvic Ultra Hypofractionated Irradiation Treatment (ePUHRT), which is an external beam radiotherapy with High Dose Rate Brachytherapy Boost (form of internal radiation where a cancer doctor implants a small plastic tube or balloon (catheter) in the tumor).
Gender:
MALE
Ages:
18 years and above
Trial Updated:
03/03/2025
Locations: Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, Indiana
Conditions: Prostate Cancer
Register for Updates
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
NCT06545942
Recruiting
This Phase 1, multi-center, open-label, dose escalation and dose optimization study is designed to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and preliminary clinical activity of MOMA-313 administered orally as a single agent or combination therapy in patients with homologous recombinant deficient solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/28/2025
Locations: Investigative Site #101, La Jolla, California +10 locations
Conditions: Advanced Solid Tumor, Metastatic Solid Tumor, Prostate Cancer, Pancreas Cancer, Breast Cancer, Ovarian Cancer, Homologous Recombination Deficiency
Register for Updates
The Evaluation of PC14586 in Patients with Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
NCT04585750
Recruiting
The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. The Phase 1 portion of the study will assess the safety, tolerability and preliminary efficacy of multiple dose levels of rezatapopt as monotherapy and in Phase 1b in combination with pembrolizumab.
Gender:
ALL
Ages:
12 years and above
Trial Updated:
02/27/2025
Locations: Hoag Cancer Center, Irvine, California +68 locations
Conditions: Advanced Solid Tumor, Advanced Malignant Neoplasm, Metastatic Cancer, Metastatic Solid Tumor, Lung Cancer, Ovarian Cancer, Endometrial Cancer, Prostate Cancer, Colorectal Cancer, Breast Cancer, Other Cancer, Locally Advanced, Head and Neck Cancer, Gall Bladder Cancer, Small Cell Lung Cancer, Small Cell Lung Cancer ( SCLC ), Small Cell Lung Carcinoma, NSCLC, NSCLC (non-small Cell Lung Cancer), SCLC, Non-Small Cell Lung Carcinoma, Triple Negative Breast Cancer, TNBC, HER2+ Breast Cancer, Non-Small Cell Lung Cancer, ER/PR Positive Breast Cancer, HER2- Breast Cancer, HER2-positive Breast Cancer, HER2-negative Breast Cancer, ER/PR(+), Her2(-) Breast Cancer
Register for Updates
Behavioral Exercise Training to Reduce Cardiovascular Disease Risk
NCT06237179
Recruiting
To test the preliminary effectiveness of a home-based exercise training (ET) intervention to improve exercise capacity (VO2 peak \& 6-minute walk distance \[6MWD\]) among prostate cancer (PC) patients compared to controls receiving healthy living education (HLE) at 12 weeks.
Gender:
MALE
Ages:
Between 40 years and 85 years
Trial Updated:
02/26/2025
Locations: Richmond Veterans Affairs Medical Center, Richmond, Virginia +1 locations
Conditions: Prostate Cancer, Supportive Care
Register for Updates
Debunking the Frailty-sarcopenIa-ADT Axis in mEtastatic Prostate canceR With multiComponent Exercise: The FIERCE Trial
NCT06040125
Recruiting
The purpose of this study is to determine whether a 16-week supervised, clinic-based circuit training intervention utilizing resistance and functional exercises and self-directed aerobic exercise will improve frailty and sarcopenic status and disease progression outcomes among pre-frail/frail metastatic prostate cancer patients receiving androgen deprivation therapy (ADT). The names of the study intervention involved in this study is: • Supervised circuit training (aerobic and resistance exerc... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
02/25/2025
Locations: Beth Israel Deaconess Medical Center, Boston, Massachusetts +2 locations
Conditions: PROSTATE CANCER, Metastatic Prostate Cancer, Metastatic Prostate Carcinoma
Register for Updates
Study of PSMA PET/MR Guided Stereotactic Body Radiation Therapy With Simultaneous Integrated Boost (SBRT-SIB) for High-Intermediate and High Risk Prostate Cancer
NCT04402151
Recruiting
This is a single-arm Phase II clinical trial assessing the clinical efficacy of prostate specific membrane antigen (PSMA) PET/MR guided MR-LINAC based SBRT-SIB with planned accrual of 50 patients.
Gender:
MALE
Ages:
Between 21 years and 90 years
Trial Updated:
02/25/2025
Locations: Weill Cornell Medicine, New York, New York
Conditions: Prostate Cancer
Register for Updates
Stereotactic Ablative Radiation Therapy for Prostate Cancer
NCT05668351
Recruiting
This single arm trial will investigate a novel way to plan and deliver SABR for prostate cancer. Prostate-directed SABR will be high-dose SABR (40 Gy in 5 fractions) with central sparing of the urethra and peripheral sparing of the rectum and pudendal arteries (SUPR-SABR). This study tests the hypothesis that genitourinary (GU) and gastrointestinal (GI) toxicity rates following SUPR-SABR are comparable to (or possibly lower than) historical GU and GI toxicity rates following standard SABR (stSAB... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
02/25/2025
Locations: Medical University of South Carolina Hollings Cancer Center, Charleston, South Carolina
Conditions: Prostate Cancer
Register for Updates
Intensive Cholesterol-Lowering and CD8+ T Cells in Prostate Cancer
NCT06437574
Recruiting
To test the hypothesis that intensive cholesterol lowering (iCL) therapy has anti-tumor immune modulating activity, the investigators will conduct an open-label, single-arm phase II trial in prostate cancer patients who are in active surveillance and undergoing a planned surveillance biopsy in 3-6 months. Eligible patients will initiate iCL with Vytorin®(group 1, 2, and 3), an FDA-approved combination of ezetimibe and simvastatin used to lower atherogenic low density lipoprotein cholesterol (LDL... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
02/25/2025
Locations: Cedars-Sinai Medical Center, Los Angeles, California
Conditions: Prostate Cancer
Register for Updates
Pilot Study of (MR) Imaging with Pyruvate (13C) to Detect High Grade Prostate Cancer
NCT02526368
Recruiting
This pilot clinical trial studies how well magnetic resonance spectroscopic imaging (MRSI) with hyperpolarized carbon 13 (13C) pyruvate alone or in combination with 13C 15N2 Urea works in finding prostate cancer that exhibits poorly differentiated or undifferentiated cells (high-grade) and that is restricted to the site of origin, without evidence of spread (localized) in patients undergoing radical prostatectomy. Diagnostic procedures, such as MRSI with hyperpolarized carbon (13C) pyruvate, may... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
02/24/2025
Locations: University of California, San Francisco, San Francisco, California
Conditions: Prostate Cancer, Localized Prostate Carcinoma
Register for Updates
Non-significant Risk (NSR) Study of [68Ga]-PSMA-11 (Illuccix) as a BgRT BioGuide on RefleXion X1
NCT06353321
Recruiting
To qualitatively determine the imaging performance of PET-CT imaging subsystem of the RefleXion X1 System Device in patients undergoing standard-of-care (SOC) \[68Ga\]-PSMA-11 PET-CT using Illuccix on the same day.
Gender:
MALE
Ages:
All
Trial Updated:
02/24/2025
Locations: Ut Southwestern Medical Center, Dallas, Texas
Conditions: Prostate Cancer
Register for Updates
Exercise for Tumor Suppressive Impact in Black Men With Prostate Cancer on Active Surveillance: The REMOVE Trial
NCT05918263
Recruiting
The purpose of this study is to determine whether a 16-week, home-based, virtually supervised exercise program will slow cancer progression of prostate cancer among Black men with prostate cancer undergoing active surveillance. The name of the study intervention involved in this study is: Aerobic high-intensity interval training (HIIT) (training exercise intervention)
Gender:
MALE
Ages:
18 years and above
Trial Updated:
02/21/2025
Locations: Beth Israel Deaconess Medical Center, Boston, Massachusetts +2 locations
Conditions: Prostate Cancer, Prostatic Neoplasms
Register for Updates
Difluoromethylornithine and High Dose Testosterone With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer
NCT06059118
Recruiting
Asymptomatic patients with metastatic castrate resistant prostate cancer (mCRPC) without pain due to prostate cancer will be treated on an open label study to evaluate effectiveness of sequential treatment with the combination of difluoromethylornithine (DFMO) and high dose testosterone in sequence with enzalutamide to improve primary and secondary outcomes.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
02/21/2025
Locations: Johns Hopkins University: Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland
Conditions: Prostate Cancer
Register for Updates